Envair Technology has reported an 18% year-on-year rise in international sales.
Almost 40% of the group’s total revenues at the end of FY21 came from international markets, compared to 33% at the end of the previous year. This global growth has been led primarily by our ONFAB brand, which specialises in designing, manufacturing and installing flexible isolators for the pharmaceutical process manufacturing industry.
Progress internationally has continued, with ONFAB recording a 154% rise in sales in the Americas in Q1 2022 alone, compared to the whole of 2021. ONFAB has seen substantial growth in orders from global contract and development manufacturing organisations (CDMOs) as more businesses understand the benefits of using flexible containment for existing processes. We are now forecasting that we will hit several million in sales for the US market by the end of this financial year.
At the same time, our Envair brand, which provides clean air solutions for the medical and drug development sectors, is enjoying expansion in Europe. It received a large increase in orders from customers in Ireland and Germany during the first quarter of 2022.
This significant international growth follows on from our decision to bring more of our manufacturing processes in-house, and consolidate the production of our rigid containment and fume cupboard lines in a new facility in Heywood, Greater Manchester in order to deliver faster turnaround times.
Andrew Ellison, CEO of Envair Technology, said:
“One of our key business aims is to continue expanding our presence overseas so it’s really pleasing to see new projects in the USA and Europe. We expect that the growing demand we’re seeing for containment solutions will lead to further international expansion by the end of this year.”
